Piramal Pharma Limited Announces Successful Closure of US FDA Inspection at Telangana Facility
Piramal Pharma Limited confirmed on May 18, 2026, that the U.S. Food and Drug Administration (US FDA) has successfully closed the inspection process at its manufacturing facility located in Digwal, Telangana, India.The confirmation follows an initial intimation regarding the US FDA inspection at the Digwal facility. Piramal Pharma Limited reported that the US FDA has issued an Establishment Inspection Report (EIR), signaling the successful completion and closure of the inspection by the agency.
The company provided the update on May 18, 2026, noting that this report was received and subsequently confirmed on the first working day following its receipt.
PPLPHARMA Stock Price Movement
As of 12:21 PM, shares of Piramal Pharma Limited are slipping by 0.71% in live trading, currently holding at ₹173.62. Trading over 1.36 million shares today, the stock continues to navigate its day's range, having fallen from its prior open near ₹174.00.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.